BMO Capital analyst Evan Seigerman lowered the firm’s price target on AbbVie (ABBV) to $208 from $228 and keeps an Outperform rating on ...

The global body contouring treatments market growth forecasted to transform from USD 1.46 billion in 2024 to USD 2.58 billion ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The foundation donation will go toward construction of UChicago Medicine's $815 million freestanding cancer care center in ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

This Ontario listing comes two months after Canada's Drug Agency (formerly CADTH) issued a reimbursement recommendation for VRAYLAR, and just days after AbbVie successfully reached an agreement ...

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...

AbbVie cautions that these forward-looking statements ... achieving in-play patient leadership across all lines of therapy in the U.S, Japan and Canada. Skyrizi’s U.S. in-play patient share ...

Welcome to the AbbVie third quarter 2024 earnings conference call. [Operator instructions] I would now like to introduce Ms.

View upcoming earnings forecasts and in-depth analysis of company forecasts.